USE OF LHAT FOR TREATING ANEMIA AND DYSFUNCTION OF RED BLOOD CELLS

摘要

1. A method of treating a patient having a condition characterized by anemia or dysfunction of red blood cells, comprising administering to the patient a therapeutically effective amount of an agent that increases either the activity of LHAT or the level of LHAT in plasma or has both effects. The method according to claim 1, where the agent is LHAT. 3. The method according to claim 1, where the agent is a drug that increases the activity or level of endogenous LHAT. The method of claim 1, wherein the agent is a gene therapy vector. The method according to claim 2, where the amount of LHAT is an amount that increases the concentration of LHAT to a level exceeding the normal level of LHAT, or the activity of LHAT to a level exceeding the normal activity of LHAT. The method of claim 5, wherein the condition is characterized by red blood cells with reduced deformability, reduced oxygenation, increased aggregation and adhesion, decreased nitric oxide function, reduced lifespan, or any combination of the above phenomena. The method of claim 5, wherein the condition is anemic. The method of claim 5, wherein the condition is sickle cell disease, diabetes, thalassemia, rheumatoid disease, autoimmune disease, arthritis, liver disease, cirrhosis, hepatitis, acanthocytosis, sepsis, dementia, anemia or microvascular disorder, inflammatory disease, parasitic disease , erectile dysfunction, cancer, preeclampsia, critical illness or injury. 9. The method of claim 8, wherein the inflammatory disease is sepsis, rheumatoid disease, anemia of inflammation, or inflammation after surgery. How